Advertisement


David M. O’Malley, MD, on Ovarian Cancer: Early Results From the FORWARD II Study

2018 ASCO Annual Meeting

Advertisement

David M. O’Malley, MD, of The Ohio State University College of Medicine, discusses phase Ib study findings on mirvetuximab soravtansine, a folate receptor alpha-targeting antibody-drug conjugate, in combination with bevacizumab in patients with platinum-resistant ovarian cancer (Abstract 5549).



Related Videos

Lung Cancer
Immunotherapy

Gilberto Lopes, MD, MBA, on NSCLC: Results From the KEYNOTE-042 Trial

Gilberto Lopes, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, discusses phase III findings on pembrolizumab vs platinum-based chemotherapy as fi...

Breast Cancer

Peter Schmid, MD, PhD, on Triple-Negative Breast Cancer: Results From the PAKT Trial

Peter Schmid, MD, PhD, of Queen Mary University of London, discusses phase II study findings on AZD5363 plus paclitaxel vs placebo plus paclitaxel as first-line therapy for metasta...

Lung Cancer

Geoffrey R. Oxnard, MD, on Lung Cancer: Results From the Circulating Cancer Genome Atlas Study

Geoffrey R. Oxnard, MD, of Dana-Farber Cancer Institute, discusses genome-wide sequencing for early-stage lung cancer detection from plasma cell–free DNA (Abstract LBA8501).

Kidney Cancer
Immunotherapy

David F. McDermott, MD, on RCC: Results of the KEYNOTE-427 Trial

David F. McDermott, MD, of Beth Israel Deaconess Medical Center, discusses study findings on pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carci...

Breast Cancer

Gabriel N. Hortobagyi, MD, on Breast Cancer Staging: New and Important Changes

Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses the 8th edition of the TNM staging system, which includes prognostic stage groups based o...

Advertisement

Advertisement



Advertisement